CSI Market
Sign In | Register

Lexaria Bioscience (LEXX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access LEXX Annual Cash Flow →
The table below presents a historical view of Lexaria Bioscience's cash flow activity, supporting analysis of liquidity trends over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(May 31 2026)
9 Months 		(Feb 28 2026) (Nov 30 2025) (Aug 31 2025) (May 31 2025)
Operating Activities
Income-5.04
Depreciation & amortization0.10
Amortization of Other Assets-0.04
Accretion Expense0.01
Impairment of Intangible Assets, Finite-lived0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.24
Noncash Contribution Expense0.00
Adjustment of Warrants Granted for Services0.00
Consulting Debt Settlement-
Share Issued For Rent-
Professional And Contract Services Expense-
Write Off Of Oil And Gas Properties Cash Flows-
Research And Development Noncash Expense-
Mmj Joint Venture-
Operating Income Loss-
Non- Cash Consideration For Licensing Revenue-
Noncash Right Of Use Lease Expense-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Realized Loss On Disposal Of Marketable Securities-
Noncash Lease Expense-
Marketable Securities Unrealized Gain Loss0.02
Increase Decrease In Operating Lease Liability-0.02
Income taxes0.00
Gain (Loss) on Sales of Loans, Net0.00
Increase (Decrease) in Accounts Receivable-0.32
Increase (Decrease) in Accounts Payable and Accrued Liabilities-1.11
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.73
Other Working Capital0.00
Other Noncash Expense0.02
Other net-0.01
Payments for (Proceeds from) Other Operating Activities2.11
Discontinued operations0.00
Net Cash flow from Operating Activities-4.78
Investing Activities
Capital Expenditures-0.09
Sale of Capital Items0.00
Proceeds from Sale of Short-term Investments6.50
Short-term Investments Acq.0.00
Real Estate Investments0.00
Investment From Altria Note-
Disposal Of Asset-
Disposal Of Assets-
Asset Disposition-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-6.50
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.09
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock6.52
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Net Change Interest-bearing Deposits, Foreign0.00
Other financing activities net0.00
Other net0.00
Proceeds From Payments Of Loans To Convertible Debentures-
Discontinued Operations Change In Working Capital-
Repayment Of Loan Payable-
Long Term Loan-
Lease Payments-
Proceed From Payment For Lease Payments-
Finance Lease Principal Payments-
Proceeds From Exercise Of Stock Options-
Proceeds From Issuance Of Common Stock For Cash-
Proceeds From Exercise Of Warrants-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents1.80
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities6.52
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-4.87
Total Cash Flow1.67
4 historic quarters locked

Sign in to unlock the full Lexaria Bioscience cash flow history.

Sign In Create Free Account

About Lexaria Bioscience Corp Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260531)
  • Filed with the SEC: July 13, 2026
  • Source: lxrp_10q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001640334-26-001166

Figures are derived from filed reports and may be restated. Historical data is subject to revision.